litlas
Log inCreate account

Peter A. Fasching

Active 2005–2025

Also published as
Peter A Fasching
439
Papers
64,793
Citations
117
h-index
387
i10-index

Citations

Citations per year for Peter A. Fasching1971: 1 citations1982: 1 citations1991: 1 citations1995: 2 citations1998: 2 citations1999: 6 citations2001: 1 citations2003: 1 citations2004: 1 citations2005: 1 citations2006: 7 citations2007: 14 citations2008: 12 citations2009: 18 citations2010: 66 citations2011: 65 citations2012: 189 citations2013: 339 citations2014: 404 citations2015: 536 citations2016: 652 citations2017: 691 citations2018: 671 citations2019: 2,259 citations2020: 3,022 citations2021: 3,180 citations2022: 2,757 citations2023: 2,211 citations2024: 3,396 citations2025: 1,763 citations2026: 47 citations1972–1981: no citations, so these years are not shown1983–1990: no citations, so these years are not shown1992–1994: no citations, so these years are not shown1996–1997: no citations, so these years are not shown2000: no citations, so this year is not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 5,638 citing papers, 19.2% of this breakdownChina: 2,810 citing papers, 9.6% of this breakdownUnited Kingdom: 1,939 citing papers, 6.6% of this breakdownGermany: 1,685 citing papers, 5.8% of this breakdownItaly: 1,506 citing papers, 5.1% of this breakdownFrance: 1,122 citing papers, 3.8% of this breakdownAustralia: 1,071 citing papers, 3.7% of this breakdownSpain: 1,066 citing papers, 3.6% of this breakdownCanada: 1,063 citing papers, 3.6% of this breakdownNetherlands: 837 citing papers, 2.9% of this breakdownSweden: 640 citing papers, 2.2% of this breakdownJapan: 635 citing papers, 2.2% of this breakdown
0%19.2%Other 31.7%

Institutions

Fields

  • Medicine50.8%
  • Biochemistry, Genetics and Molecular Biology37.4%
  • Immunology and Microbiology3.2%
  • Computer Science2.3%
  • Engineering1.1%
  • Neuroscience0.8%
  • Other4.4%

Topics

  • Breast Cancer Treatment Studies7.2%
  • HER2/EGFR in Cancer Research4.7%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Advanced Breast Cancer Therapies3.8%
  • Cancer Genomics and Diagnostics3%
  • BRCA gene mutations in cancer2.9%
  • Other74.3%

Coauthors

All papers

Open in search
  1. Pembrolizumab for Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy - New England Journal of Medicine 2020 cited by 3,116

  2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    Authors: Patricia Cortazar, Lijun Zhang, Michael Untch, Keyur Mehta, Joseph P. Costantino, Norman Wolmark, Hervé Bonnefoi, David Cameron, Luca Gianni, Pinuccia Valagussa, Sandra M. Swain, Tatiana M. Prowell, Sibylle Loibl, D. Lawrence Wickerham, Jan Bogaerts, José Baselga, Charles M. Perou, Gideon M. Blumenthal, Jens‐Uwe Blohmer, Eleftherios P. Mamounas, Jonas Bergh, Semiglazov Vf, Robert Justice, Holger Eidtmann, Soonmyung Paik, Martine Piccart, Rajeshwari Sridhara, Peter A. Fasching, Leen Slaets, Shenghui Tang, Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 cited by 4,710

  3. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

    Authors: Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer - New England Journal of Medicine 2018 cited by 2,618

  4. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Michael Untch, Peter A. Fasching, Fatima Cardoso, Jay Andersen, Debra Patt, Michael Danso, Marta Ferreira, Marie-Ange Mouret-Reynier, Seock-Ah Im, Jin-Hee Ahn, Maria Gion, Sally Baron-Hay, Jean-François Boileau, Yu Ding, Konstantinos Tryfonidis, Gursel Aktan, Vassiliki Karantza, Joyce O’Shaughnessy - New England Journal of Medicine 2022 cited by 1,145

  5. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

    Authors: Carsten Denkert, Gϋnter von Minckwitz, Silvia Darb‐Esfahani, Bianca Lederer, Barbara Ingold Heppner, Karsten E. Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto, Wolfgang Schmitt, Jens‐Uwe Blohmer, Thomas Karn, Berit M. Pfitzner, Sherko Kümmel, Knut Engels, Andreas Schneeweiß, Arndt Hartmann, Aurelia Noske, Peter A. Fasching, Christian Jackisch, Marion van Mackelenbergh, Hans‐Peter Sinn, Christian Schem, Claus Hanusch, Michael Untch, Sibylle Loibl - The Lancet Oncology 2017 cited by 2,125

  6. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

    Authors: Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer, Serban Dan Costa, Holger Eidtmann, Peter A. Fasching, Bernd Gerber, W. Eiermann, J. Hilfrich, Jens Huober, Christian Jackisch, Manfred Kaufmann, Gottfried E. Konecny, Carsten Denkert, Valentina Nekljudova, Keyur Mehta, Sibylle Loibl - Journal of Clinical Oncology 2012 cited by 2,674

  7. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Authors: Dennis J. Slamon, Patrick Neven, Stephen Chia, Peter A. Fasching, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, Francisco J. Esteva, Miguel Martín, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Xavier Pivot, Gena Vidam, Yingbo Wang, Karen Rodriguez Lorenc, Michelle C. Miller, Tetiana Taran, Guy Jérusalem - Journal of Clinical Oncology 2018 cited by 1,112

  8. Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Authors: Nasim Mavaddat, Kyriaki Michailidou, Joe Dennis, Michael Lush, Laura Fachal, Andrew Lee, Jonathan P. Tyrer, Ting‐Huei Chen, Qin Wang, Manjeet K. Bolla, Xin Yang, Muriel A. Adank, Thomas U. Ahearn, Kristiina Aittomäki, Jamie Allen, Irene L. Andrulis, Hoda Anton‐Culver, Natalia Antonenkova, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Päivi Auvinen, Myrto Barrdahl, Laura E. Beane Freeman, Matthias W. Beckmann, Sabine Behrens, Javier Benı́tez, Marina Bermisheva, Leslie Bernstein, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Bernardo Bonanni, Anne‐Lise Børresen‐Dale, Hiltrud Brauch, Michael Bremer, Hermann Brenner, Adam R. Brentnall, Ian W. Brock, Angela Brooks‐Wilson, Sara Y. Brucker, Thomas Brüning, Barbara Burwinkel, Daniele Campa, Brian D. Carter, Jose E. Castelao, Stephen J. Chanock, Rowan T. Chlebowski, Hans Christiansen, Christine L. Clarke, J. Margriet Collée, Emilie Cordina‐Duverger, Sten Cornelissen, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dörk, Isabel dos‐Santos‐Silva, Martine Dumont, Lorraine Durcan, Miriam Dwek, Diana M. Eccles, Arif B. Ekici, A. Heather Eliassen, Carolina Ellberg, Christoph Engel, Mikael Eriksson, D. Gareth Evans, Peter A. Fasching, Jonine D. Figueroa, Olivia Fletcher, Henrik Flyger, Asta Försti, Lin Fritschi, Marike Gabrielson, Manuela Gago-Domínguez, Susan M. Gapstur, José Á. García-Sáenz, Mia M. Gaudet, V. Georgoulias, Graham G. Giles, I. R. Gilyazova, Gord Glendon, Mark S. Goldberg, David E. Goldgar, Anna González‐Neira, Grethe I.G. Alnæs, Mervi Grip, Jacek Gronwald, Anne Grundy, Pascal Guénel, Lothar Haeberle, Eric Hahnen, Christopher A. Haiman, Niclas Håkansson, Ute Hamann, Susan E. Hankinson and 169 more - The American Journal of Human Genetics 2018 cited by 1,183

  9. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

    Authors: Carsten Denkert, Fenja Seither, Andreas Schneeweiß, Theresa Link, Jens‐Uwe Blohmer, Marianne Just, Pauline Wimberger, A Forberger, Hans Tesch, Christian Jackisch, Sabine Schmatloch, Mattea Reinisch, Erich Solomayer, Wolfgang Schmitt, Claus Hanusch, Peter A. Fasching, Kristina Lübbe, Christine Solbach, Jens Huober, Kerstin Rhiem, Frederik Marmé, Toralf Reimer, Marcus Schmidt, Bruno V. Sinn, Wolfgang Janni, Elmar Stickeler, Laura L. Michel, Oliver Stötzer, Eric Hahnen, Jenny Furlanetto, Sabine Seiler, Valentina Nekljudova, Michael Untch, Sibylle Loibl - The Lancet Oncology 2021 cited by 561

  10. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

    Authors: Dennis J. Slamon, Patrick Neven, Stephen Chia, Peter A. Fasching, Michelino De Laurentiis, Seock‐Ah Im, Katarína Petráková, Giulia Bianchi, Francisco J. Esteva, Miguel Martín, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Xavier Pivot, Manu Sondhi, Yingbo Wang, Arunava Chakravartty, Karen Rodriguez-Lorenc, Tetiana Taran, Guy Jérusalem - New England Journal of Medicine 2019 cited by 841

  11. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

    Authors: S. Loibl, Michael Untch, Nicole Burchardi, Jens Huober, Bruno V. Sinn, Jens‐Uwe Blohmer, Eva‐Maria Grischke, Jenny Furlanetto, Hans Tesch, Claus Hanusch, Knut Engels, Mahdi Rezai, Christian Jackisch, Wolfgang Schmitt, Gϋnter von Minckwitz, Jörg Thomalla, Sherko Kümmel, Beate Rautenberg, Peter A. Fasching, Karsten E. Weber, Kerstin Rhiem, Carsten Denkert, Andreas Schneeweiß - Annals of Oncology 2019 cited by 694

  12. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    Authors: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 cited by 357

  13. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

    Authors: Sibylle Loibl, Andreas Schneeweiß, Jens Huober, Michael Braun, Julia Rey, Jens‐Uwe Blohmer, Jenny Furlanetto, D M Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch, Peter Staib, Theresa Link, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Valentina Nekljudova, Carsten Denkert, Michael Untch - Annals of Oncology 2022 cited by 244

  14. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

    Authors: Peter Schmid, Javier Cortes, Rebecca Dent, Heather L. McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock‐Ah Im, Michael Untch, Peter A. Fasching, Marie‐Ange Mouret‐Reynier, Theodoros Foukakis, Marta Ferreira, Fátima Cardoso, Xuan Zhou, Vassiliki Karantza, Konstantinos Tryfonidis, Gursel Aktan, Joyce O’Shaughnessy - New England Journal of Medicine 2024 cited by 419

  15. Genetic insights into biological mechanisms governing human ovarian ageing

    Authors: Katherine S. Ruth, Felix R. Day, Jazib Hussain, Ana Martínez-Marchal, Catherine Aiken, Ajuna Azad, Deborah J. Thompson, Lucie Knoblochová, Hironori Abe, Jane L. Tarry‐Adkins, Javier Martín‐González, Pierre Fontanillas, Annique Claringbould, Olivier B. Bakker, Patrick Sulem, Robin Walters, Chikashi Terao, Sandra Turon, Momoko Horikoshi, Kuang Lin, N. Charlotte Onland‐Moret, Aditya Sankar, Emil Peter Thrane Hertz, Pascal Timshel, Vallari Shukla, Rehannah Borup, Kristina Wendelboe Olsen, Paula Aguilera, Mònica Ferrer‐Roda, Yan Huang, Stasa Stankovic, Paul R. H. J. Timmers, Thomas U. Ahearn, Behrooz Z. Alizadeh, Elnaz Naderi, Irene L. Andrulis, Alice M. Arnold, Kristan J. Aronson, Annelie Augustinsson, Stefania Bandinelli, Caterina Barbieri, Robin N. Beaumont, Heiko Becher, Matthias W. Beckmann, Stefania Benónísdóttir, Sven Bergmann, Murielle Bochud, Eric Boerwinkle, Stig E. Bojesen, Manjeet K. Bolla, Dorret I. Boomsma, Nicholas Bowker, Jennifer A. Brody, Linda Broer, Julie E. Buring, Archie Campbell, Harry Campbell, Jose E. Castelao, Eulalia Catamo, Stephen J. Chanock, Georgia Chenevix‐Trench, Marina Ciullo, Tanguy Corre, Fergus J. Couch, Angela Cox, Laura Crisponi, Simon S. Cross, Francesco Cucca, Kamila Czene, George Davey Smith, Eco J. C. de Geus, Renée de Mutsert, Immaculata De Vivo, Ellen W. Demerath, Joe Dennis, Alison M. Dunning, Miriam Dwek, Mikael Eriksson, Tõnu Esko, Peter A. Fasching, Jessica D. Faul, Luigi Ferrucci, Nora Franceschini, Timothy M. Frayling, Manuela Gago-Domínguez, Massimo Mezzavilla, Montserrat García‐Closas, Christian Gieger, Graham G. Giles, Harald Grallert, Daníel F. Guðbjartsson, Vilmundur Guðnason, Pascal Guénel, Christopher A. Haiman, Niclas Håkansson, Per Hall, Caroline Hayward, Chunyan He, Wei He, Gerardo Heiss and 174 more - Nature 2021 cited by 447

  16. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

    Authors: Haoyu Zhang, Thomas U. Ahearn, Julie Lecarpentier, Daniel R. Barnes, Jonathan Beesley, Guanghao Qi, Xia Jiang, Tracy A. O’Mara, Ni Zhao, Manjeet K. Bolla, Alison M. Dunning, Joe Dennis, Qin Wang, Zumuruda Abu Ful, Kristiina Aittomäki, Irene L. Andrulis, Hoda Anton‐Culver, Volker Arndt, Kristan J. Aronson, Banu Arun, Paul L. Auer, Jacopo Azzollini, Daniel Barrowdale, Heiko Becher, Matthias W. Beckmann, Sabine Behrens, Javier Benı́tez, Marina Bermisheva, Katarzyna Białkowska, Ana Blanco, Carl Blomqvist, Natalia Bogdanova, Stig E. Bojesen, Bernardo Bonanni, Davide Bondavalli, Åke Borg, Hiltrud Brauch, Hermann Brenner, Ignacio Briceño, Annegien Broeks, Sara Y. Brucker, Thomas Brüning, Barbara Burwinkel, Saundra S. Buys, Helen Byers, Trinidad Caldés, Maria A. Caligo, Mariarosaria Calvello, Daniele Campa, Jose E. Castelao, Jenny Chang‐Claude, Stephen J. Chanock, Melissa Christiaens, Hans Christiansen, Wendy K. Chung, Kathleen Claes, Christine L. Clarke, Sten Cornelissen, Fergus J. Couch, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Peter Devilee, Orland Dı́ez, Susan M. Domchek, Thilo Dörk, Miriam Dwek, Diana M. Eccles, Arif B. Ekici, D. Gareth Evans, Peter A. Fasching, Jonine D. Figueroa, Lenka Foretová, Florentia Fostira, Eitan Friedman, Debra Frost, Manuela Gago-Domínguez, Susan M. Gapstur, Judy E. Garber, José Á. García-Sáenz, Mia M. Gaudet, Simon A. Gayther, Graham G. Giles, Andrew K. Godwin, Mark S. Goldberg, David E. Goldgar, Anna González‐Neira, Mark H. Greene, Jacek Gronwald, Pascal Guénel, Lothar Häberle, Eric Hahnen, Christopher A. Haiman, Christopher R. Hake, Per Hall, Ute Hamann, Elaine F. Harkness, Bernadette A. M. Heemskerk‐Gerritsen, Peter Hillemanns and 176 more - Nature Genetics 2020 cited by 567

  17. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

    Authors: Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, María Ángeles Fernández, Z. Liu, Hiroyuki Yasojima, Yu Ding, L. Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia - Annals of Oncology 2023 cited by 134

  18. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

    Authors: Gϋnter von Minckwitz, Andreas Schneeweiß, Sibylle Loibl, Christoph Salat, Carsten Denkert, Mahdi Rezai, Jens‐Uwe Blohmer, Christian Jackisch, Stefan Paepke, Bernd Gerber, Dirk M. Zahm, Sherko Kümmel, Holger Eidtmann, Peter Klare, Jens Huober, Serban Dan Costa, Hans Tesch, Claus Hanusch, J. Hilfrich, F Khandan, Peter A. Fasching, Bruno V. Sinn, Knut Engels, Keyur Mehta, Valentina Nekljudova, Michael Untch - The Lancet Oncology 2014 cited by 1,030

  19. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Authors: Nadia Harbeck, Priya Rastogi, Miguel Martín, Sara M. Tolaney, Zhimin Shao, Peter A. Fasching, Chiun‐Sheng Huang, Georgina Garnica Jaliffe, A. Tryakin, Matthew P. Goetz, Hope S. Rugo, Elżbieta Senkus, Laura Testa, Mariette Andersson, Kenji Tamura, Lucia Del Mastro, Guenther G. Steger, Hans Kreipe, Roberto Hegg, Joohyuk Sohn, Valentina Guarneri, Javier Cortés, E.P. Hamilton, Valérie André, Ran Wei, Susana Barriga, S. Sherwood, Tammy Forrester, Montserrat Muñoz-Mateu, Ashwin Shahir, Belén San Antonio, Sarah C. Nabinger, Masakazu Toi, Stephen Johnston, Joyce O’Shaughnessy, M.M. Jimenez, Stephen Johnston, F. Boyle, Guenther G. Steger, Patrick Neven, Zefei Jiang, Mario Campone, Jens Huober, Chikako Shimizu, I. Cicin, Andrew Wardley, Sara M. Tolaney, Gonzalo Gómez Abuin, J. J. Zarba, Elgene Lim, P. Sant, Naishun Liao, Bo Christiansen, Natalja Eigėlienė, J. Martin-Babau, Johannes Ettl, D. Mavroudis, Joanne Chiu, Katalin Boér, R. Nagarkar, Shani Paluch–Shimon, Luca Moscetti, Yoshiatsu Sagara, S.-B. Kim, Rui M. B. Maciel, Vivianne C. G. Tjan‐Heijnen, Reuben Broom, Aleksandra Łacko, M. Schenker, Nikita Volkov, Yoon Sim Yap, M.A. Coccia-Portugal, J. Ángel García Sáenz, Anne Andersson, Tai-Jong Chao, Erhan Gökmen, Hakan Harputluoğlu, O. Berzoy, Debra A. Patt, Heather L. McArthur, Helen K. Chew, Pavani Chalasani, Peter A. Kaufman, Karen L. Tedesco, Stephanie L. Graff - Annals of Oncology 2021 cited by 378

  20. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Authors: Dennis J. Slamon, Patrick Neven, Stephen Chia, Guy Jérusalem, Michelino De Laurentiis, Sin‐Hyeog Im, Katarína Petráková, Giulia Bianchi, Miguel Martín, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz‐Merino, J. Thaddeus Beck, Yan Ji, C. Wang, Uday Deore, A. Chakravartty, Juan Pablo Zarate, T Taran, Peter A. Fasching - Annals of Oncology 2021 cited by 278

  21. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

    Authors: Richard J. Gray, Rosie Bradley, Jeremy Braybrooke, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, William E. Barlow, Judith M. Bliss, Paolo Bruzzi, David Cameron, George Fountzilas, Sibylle Loibl, John R. Mackey, Miguel Martín, Lucia Del Mastro, Volker Möbus, Valentina Nekljudova, Sabino De Placido, Sandra M. Swain, Michael Untch, Kathleen I. Pritchard, Jonas Bergh, Larry Norton, Clare Boddington, Julie Ann Burrett, Mike Clarke, Christina Davies, Frances Duane, Vaughan Evans, Lucy Gettins, Jon Godwin, Robert K. Hills, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Yaochen Wang, Zhe Wang, Peter A. Fasching, Nadia Harbeck, Pascal Piedbois, Michael Gnant, Guenther G. Steger, Angelo Di Leo, Stella Dolci, Prue Francis, Denis Larsimont, J.-M. Nogaret, C. Philippson, Martine Piccart, Sabine C. Linn, Petronella G.M. Peer, Vivianne C. G. Tjan‐Heijnen, S.B. Vliek, John R. Mackey, Dennis Slamon, John M.S. Bartlett, Vivien Bramwell, Bingshu E. Chen, Stephen Chia, Karen A. Gelmon, Paul E. Goss, Mark N. Levine, Wendy R. Parulekar, Joseph L. Pater, Eileen Rakovitch, Lois E. Shepherd, Dongsheng Tu, Timothy J. Whelan, Donald A. Berry, Gloria Broadwater, Constance Cirrincione, Hyman B. Muss, Raymond L. Weiss, Yi Shan, Yong fu Shao, Xiang Wang, Binghe Xu, Dongbing Zhao, Harry Bartelink, Nina Bijker, Jan Bogaerts, Fátima Cardoso, Tanja Čufer, Jean‐Pierre Julien, Philip Poortmans, Emiel J. Rutgers, Cornelis J.�H. van de Velde, Eva Carrasco, Miguel Ángel Seguí, Jens‐Uwe Blohmer, Serban Dan Costa, Bernd Gerber and 67 more - The Lancet 2019 cited by 394

  22. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

    Authors: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Bella Kaufman, Rinat Yerushalmi, Peter A. Fasching, Jeffrey L. Nordstrom, Ezio Bonvini, Scott Koenig, Sutton Edlich, Shengyan Hong, Edwin P. Rock, William J. Gradishar, SOPHIA Study Group - JAMA Oncology 2021 cited by 349

  23. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

    Authors: Thomas Karn, Carsten Denkert, Karsten E. Weber, Uwe Holtrich, Claus Hanusch, Bruno V. Sinn, Brandon W. Higgs, Paul Jank, Hans‐Peter Sinn, Jens Huober, Christoph Becker, Jens‐Uwe Blohmer, Frederik Marmé, Wolfgang Schmitt, Song Wu, Marion van Mackelenbergh, Volkmar Müller, Christian Schem, Elmar Stickeler, Peter A. Fasching, Christian Jackisch, Michael Untch, Andreas Schneeweiß, Sibylle Loibl - Annals of Oncology 2020 cited by 238

  24. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

    Authors: Dennis J. Slamon, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, Fran Visco, Rodrigo Fresco, Tetiana Taran, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2023 cited by 139